Clinical Scorecard: Intismeran may improve melanoma end points
At a Glance
| Category | Detail |
|---|---|
| Condition | Stage IIB to IV cutaneous melanoma |
| Key Mechanisms | Combination of individualized mRNA-based neoantigen therapy (intismeran) and pembrolizumab to stimulate T-cell responses against cancer cells. |
| Target Population | Patients with completely resected stage IIB, IIC, III, or IV cutaneous melanoma who have not received prior systemic therapy. |
| Care Setting | Adjuvant therapy following complete surgical resection. |
Key Highlights
- Intismeran plus pembrolizumab improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to pembrolizumab alone.
- The phase 3 INTerpath-001 trial enrolled 1,137 patients.
- Intismeran is an investigational therapy using tumor-specific information to create neoantigens.
- No new safety signals were reported; safety findings were consistent with previous studies.
Guideline-Based Recommendations
Diagnosis
- Patients should be diagnosed with completely resected stage IIB, IIC, III, or IV cutaneous melanoma.
Management
- Consider combination therapy of intismeran and pembrolizumab for eligible patients.
Monitoring & Follow-up
- Ongoing follow-up for secondary outcomes, including overall survival.
Risks
- Treatment may continue for approximately 1 year unless disease recurrence or unacceptable toxicity occurs.
Patient & Prescribing Data
Patients with completely resected stage IIB to IV cutaneous melanoma.
Intismeran administered at 1 mg every 3 weeks for up to nine doses, pembrolizumab at 400 mg every 6 weeks for up to 9 cycles.
Clinical Best Practices
- Utilize combination therapy in appropriate patients to improve RFS and DMFS.
- Monitor patients for disease recurrence and treatment-related toxicity.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
